Form 8-K - Current report:
SEC Accession No. 0001641172-25-025438
Filing Date
2025-08-26
Accepted
2025-08-25 20:18:16
Documents
14
Period of Report
2025-08-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 43491
2 EX-99.1 ex99-1.htm EX-99.1 13663
  Complete submission text file 0001641172-25-025438.txt   276147

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bctx-20250821.xsd EX-101.SCH 3863
4 XBRL DEFINITION FILE bctx-20250821_def.xml EX-101.DEF 26836
5 XBRL LABEL FILE bctx-20250821_lab.xml EX-101.LAB 38188
6 XBRL PRESENTATION FILE bctx-20250821_pre.xml EX-101.PRE 25516
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6493
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 251252409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)